Inflammation

Use of dupilumab was associated with significant improvement in clinical symptoms of chronic rhinosinusitis (CRS) with nasal polyps among real-world patients in Canada, with benefits shown to be similar to that observed in randomized clinical trials.

Patients with chronic rhinosinusitis (CRS) with nasal polyps identified several unmet needs regarding their condition, particularly a lack of public and physician awareness on disease burden and poor sleep quality.

An exhalation system with fluticasone was shown to significantly reduce nasal polyp score at 4 and 16 weeks compared with placebo, with improvements also observed in several patient-reported outcomes.

The lack of effective long-term control of eosinophilic esophagitis (EoE) highlights the unmet need for targeted systemic therapies.

Other gastrointestinal disorders and inflammatory diseases have also been linked to psychiatric disorders, but not much is known about the connection to eosinophilic esophagitis (EoE).

The study was conducted because information on the relationship between eosinophilic esophagitis (EOE) symptoms and biologic findings are limited, so researchers looked at the long-term effects of esophageal dilation, including patient-reported outcome (PRO) measures.

Reduced health-related quality of life was identified in patients with chronic rhinosinusitis with nasal polyps compared with the general population—regardless of previous sinus surgery or presence of comorbidities.

Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.

Circulating B cell–activating factor was shown to be a potential biomarker in identifying blood eosinophil counts and risk of postoperative nasal polyp recurrence among patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Recent clinical trials have excluded older patients with eosinophilic esophagitis (EoE) from participating; however, patients aged 65 years and older are more likely to respond to topical corticosteroids than their younger counterparts.

Young adult men with chronic rhinosinusitis with nasal polyps were shown to be at greater risk of nasal polyp recurrence after endoscopic sinus surgery than elderly men and adult women of all ages.

A recent study found a correlation in patients with an IgE-mediated food allergy (IgE-FA) reporting symptoms of eosinophilic esophagitis (EoE), leading researchers to conclude screening for EoE may be beneficial.

A child’s schooling is affected by the impact of eosinophilic esophagitis (EoE), explained Colette Romero, whose son has the disease.

A significantly greater proportion of patients with chronic rhinosinusitis with nasal polyps reported symptom-free days for at least 1 symptom when treated with dupilumab vs placebo in the 28 days preceding 24-week and 52-week analysis intervals.

Younger and older patients with noneosinophilic chronic rhinosinusitis (CRS) with nasal polyps showed significant differences in preoperative blood eosinophil levels and postoperative modified Lund-Kennedy scores.

A case report describes how an eosinophilic esophagitis diagnosis does not preclude other eosinophilic gastrointestinal diseases from developing.

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal congestion severity, whereas benralizumab was least effective.

Patients with chronic rhinosinusitis (CRS) with nasal polyps exhibited significant improvement in olfactory function when treated with a combination of oral and nasal steroids vs nasal steroids alone.

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to abstracts presenting findings from the 3-part LIBERTY-EoE-TREET study.

Eosinophilic esophagitis (EoE) is triggered by food and in this interview, Colette Romero, whose son has the disease, discusses the financial implications for families, including equity considerations.

FDA issued a complete response letter (CRL) to AstraZeneca seeking additional clinical data for benralizumab, sold as Fasenra, in the treatment of patients with inadequately controlled chronic rhinosinusitis with nasal polyps.

Patients with chronic rhinosinusitis (CRS) with severe radiographic disease were more likely to report incidence of nasal polyps and be managed by endoscopic sinus surgery, but did not show greater health care utilization.

Eosinophilic esophagitis (EoE) is still a new, rare disease and as such providers would benefit from more education about this condition, said Colette Romero, whose son has EoE.

Administering dupilumab for other atopic conditions, including atopic dermatitis (AD) and asthma, in patients who also have eosinophilic esophagitis (EoE), resulted in improved EoE symptoms.

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who have comorbidities were more likely than those without co-occuring conditions to require revision endoscopic sinus surgery over a 10-year period.